Indo US Bio-TechNSE:INDOUS +0.96%63 Current Ratio is 3.05 as of Mar. 2026, which is 11% above its 10-year median of 2.75. GuruFocus rates NSE:INDOUS with a GF Score™ of 63/100 and a GF Value™ of ₹292.74 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 260 Agriculture companies, Indo US Bio-Tech ranks better than 79.62% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Indo US Bio-Tech's current ratio for the quarter that ended in Mar. 2026 was 3.05.
Indo US Bio-Tech has a current ratio of 3.05. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Indo US Bio-Tech's Current Ratio or its related term are showing as below:
NSE:INDOUS'
s Current Ratio Range Over the Past 10 Years
Min: 1.27 Med: 2.75 Max: 5.31
Current: 3.05
During the past 13 years, Indo US Bio-Tech's highest Current Ratio was 5.31. The lowest was 1.27. And the median was 2.75.
NSE:INDOUS's Current Ratio is ranked better than 79.62% of 260
companies
in the Agriculture industry
Industry Median: 1.56
vs NSE:INDOUS: 3.05
Indo US Bio-Tech (NSE:INDOUS) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Indo US Bio-Tech Current Ratio Related Terms
Indo US Bio-Tech Current Ratio Historical Data
* Premium members only.
The historical data trend for Indo US Bio-Tech's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INDOUS vs CTVA, CF, MOS: Current Ratio Comparison
For the Agricultural Inputs subindustry, Indo US Bio-Tech's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indo US Bio-Tech Current Ratio vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Indo US Bio-Tech's Current Ratio distribution charts can be found below:
* The bar in red indicates where Indo US Bio-Tech's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indo US Bio-Tech (NSE:INDOUS) has a Current Ratio of 3.05 as of Mar. 2026. This is 11% above median its historical median of 2.75. Over the past decade, Indo US Bio-Tech's Current Ratio has ranged from 1.27 to 5.31. According to the industry distribution chart, Indo US Bio-Tech ranks #53 out of 260 companies in the Agriculture industry, placing it in the top 20.4%.
Is Indo US Bio-Tech's Current Ratio too high?
Indo US Bio-Tech's current Current Ratio of 3.05 is 11% above median its 10-year median of 2.75. Over the past 10 years, this metric has ranged from a low of 1.27 to a high of 5.31. The Agriculture industry median Current Ratio is 1.56. Indo US Bio-Tech's value of 3.05 is 95.5% above this industry median. Based on the distribution chart, Indo US Bio-Tech ranks #53 out of 260 companies in the Agriculture industry, which is in the top quartile — a strong position relative to peers. Overall, Indo US Bio-Tech has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indo US Bio-Tech's Current Ratio compare to CTVA and CF?
According to the Agriculture industry distribution chart, Indo US Bio-Tech ranks #53 out of 260 companies for Current Ratio. This places Indo US Bio-Tech in the top 20% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.56. Indo US Bio-Tech's value of 3.05 is 95.5% above this benchmark. Historically, Indo US Bio-Tech's own Current Ratio has ranged from 1.27 to 5.31 over the past decade. While the company's 10-year median is 2.75 vs. the industry median of 1.56, Indo US Bio-Tech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for an Agriculture company?
The median Current Ratio among Agriculture companies is 1.56, based on 260 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indo US Bio-Tech's current Current Ratio of 3.05 is 95.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Agriculture industry, the median Current Ratio is 1.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indo US Bio-Tech's current Current Ratio is 3.05, which is 11% above median its own 10-year median of 2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo US Bio-Tech stock overvalued right now?
Based on GuruFocus' analysis, Indo US Bio-Tech (NSE:INDOUS) is currently considered Possible Value Trap. The stock's GF Value™ is ₹292.74, compared to a current price of ₹89.15 — trading 69.5% below its estimated fair value. The current Current Ratio is 3.05, which is 11% above median its 10-year median of 2.75 and 95.5% above the Agriculture industry median of 1.56. Indo US Bio-Tech's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Indo US Bio-Tech (NSE:INDOUS), the current Current Ratio is 3.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indo US Bio-Tech (NSE:INDOUS) Overvalued in 2026?
Based on GuruFocus' analysis, Indo US Bio-Tech stock appears to be undervalued.
The current stock price of ₹89.15 is trading 69.5% below its estimated GF Value™ of ₹292.74.
GuruFocus considers Indo US Bio-Tech to be Possible Value Trap.
Key valuation signals for NSE:INDOUS:
Current Ratio: 3.05 (11% above median its 10-year median of 2.75)
GF Value™: ₹292.74 vs. price of ₹89.15 (69.5% below fair value)
Industry Position: 95.5% above the Agriculture median (#53 of 260)
No single metric tells the full story. See the NSE:INDOUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indo US Bio-Tech Ltd is a specialized agriculture seed company. It is involved in crop research and development through breeding, production of seeds, processing, packing, and marketing of high-performing hybrid and open-pollinated varieties of crops. The company's product portfolio includes a diversified variety of agricultural seeds, namely vegetable seeds, oil seeds, pulses seeds, cereals seeds, spices seeds used in cultivating all kinds of vegetables, pulses, crops like tomato, okra, brinjal, onion, bit root, cucumber, bottle gourd, groundnut, mustard, bajra, wheat, etc.
63GF Score
Get the complete analysis for NSE:INDOUS
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INDOUS has been successfully added to your 
